Guo Jing L, Braun Dylan, Fitzgerald Gabriel A, Hsieh Yun-Ting, Rougé Lionel, Litvinchuk Alexandra, Steffek Micah, Propson Nicholas E, Heffner Catherine M, Discenza Claire, Han Suk Ji, Rana Anil, Skuja Lukas L, Lin Bi Qi, Sun Elizabeth W, Davis Sonnet S, Balasundar Srijana, Becerra Isabel, Dugas Jason C, Ha Connie, Hsiao-Nakamoto Jennifer, Huang Fen, Jain Shourya, Kung Jennifer E, Liau Nicholas P D, Mahon Cathal S, Nguyen Hoang N, Nguyen Nathan, Samaddar Madhuja, Shi Yajuan, Tatarakis David, Tian Yuxi, Zhu Yuda, Suh Jung H, Sandmann Thomas, Calvert Meredith E K, Arguello Annie, Kane Lesley A, Lewcock Joseph W, Holtzman David M, Koth Christopher M, Di Paolo Gilbert
Denali Therapeutics Inc., South San Francisco, CA, USA.
Denali Therapeutics Inc., South San Francisco, CA, USA.
Cell. 2025 Jan 9;188(1):187-206.e26. doi: 10.1016/j.cell.2024.10.027. Epub 2024 Nov 11.
While apolipoprotein E (APOE) is the strongest genetic modifier for late-onset Alzheimer's disease (LOAD), the molecular mechanisms underlying isoform-dependent risk and the relevance of ApoE-associated lipids remain elusive. Here, we report that impaired low-density lipoprotein (LDL) receptor (LDLR) binding of lipidated ApoE2 (lipApoE2) avoids LDLR recycling defects observed with lipApoE3/E4 and decreases the uptake of cholesteryl esters (CEs), which are lipids linked to neurodegeneration. In human neurons, the addition of ApoE carrying polyunsaturated fatty acids (PUFAs)-CE revealed an allelic series (ApoE4 > ApoE3 > ApoE2) associated with lipofuscinosis, an age-related lysosomal pathology resulting from lipid peroxidation. Lipofuscin increased lysosomal accumulation of tau fibrils and was elevated in the APOE4 mouse brain with exacerbation by tau pathology. Intrahippocampal injection of PUFA-CE-lipApoE4 was sufficient to induce lipofuscinosis in wild-type mice. Finally, the protective Christchurch mutation also reduced LDLR binding and phenocopied ApoE2. Collectively, our data strongly suggest decreased lipApoE-LDLR interactions minimize LOAD risk by reducing the deleterious effects of endolysosomal targeting of ApoE and associated pathogenic lipids.
虽然载脂蛋白E(APOE)是晚发性阿尔茨海默病(LOAD)最强的基因修饰因子,但异构体依赖性风险背后的分子机制以及载脂蛋白E相关脂质的相关性仍不清楚。在这里,我们报告脂质化的载脂蛋白E2(lipApoE2)与低密度脂蛋白受体(LDLR)的结合受损避免了lipApoE3/E4所观察到的LDLR循环缺陷,并减少了胆固醇酯(CEs)的摄取,胆固醇酯是与神经退行性变相关的脂质。在人类神经元中,添加携带多不饱和脂肪酸(PUFAs)-CE的载脂蛋白E揭示了一个与脂褐质沉积相关的等位基因系列(ApoE4>ApoE3>ApoE2),脂褐质沉积是一种由脂质过氧化引起的与年龄相关的溶酶体病理状态。脂褐质增加了tau原纤维在溶酶体中的积累,并且在APOE4小鼠大脑中升高,并因tau病理而加剧。海马内注射PUFA-CE-lipApoE4足以在野生型小鼠中诱导脂褐质沉积。最后,具有保护作用的克赖斯特彻奇突变也减少了LDLR结合,并模拟了载脂蛋白E2的表型。总体而言,我们的数据强烈表明,减少lipApoE-LDLR相互作用可通过减少ApoE和相关致病性脂质的内溶酶体靶向的有害影响来降低LOAD风险。